What is Vapotherm?
Founded in 1999 and based in New Hampshire, Vapotherm has established itself as a key player in the medical device industry. The company's core innovation lies in its proprietary high velocity therapy (HVT) system, which delivers medical gases at precise temperatures and humidity levels through a specialized nasal cannula. This therapy is designed to improve patient comfort and clinical outcomes for a range of respiratory conditions, positioning Vapotherm as a critical provider in respiratory care solutions. The company's commitment to advancing patient care through technological innovation has been a driving force behind its sustained development and market penetration.
How much funding has Vapotherm raised?
Vapotherm has raised a total of $416.6M across 11 funding rounds:
Series A
$26.4M
Series B
$24M
Series C
$20M
Series D
$30M
Series E
$35M
Stock Offering
$64.4M
Stock Offering
$48.3M
Stock Offering
$93.8M
Debt
$52M
Series A (2013): $26.4M supported by Undisclosed
Series B (2014): $24M featuring QuestMark Partners, Kaiser Permanente, 3x5 Special Opportunity Fund, Gilde Healthcare, Integral Capital Partners, Cross Creek Capital, Adage Capital Management, and Morgenthaler Private Equity
Series C (2015): $20M backed by Crestline, Kaiser Permanente Ventures, Adage Capital Management, and Morgenthaler Private Equity
Series D (2015): $30M with participation from Gilde Healthcare, Cross Creek Capital, Adage Capital Management, Perceptive Advisors, Morgenthaler Private Equity, Arnerich massena, QuestMark Partners, Kaiser Permanente, and Crestline
Series E (2017): $35M led by Gilde Healthcare, Perceptive Advisors, Arnerich Massena, Redmile Group, Morgenthaler Private Equity, and Kaiser Permanente
Stock Issuance/Offering (2018): $64.4M supported by Undisclosed
Stock Issuance/Offering (2019): $48.3M featuring Undisclosed
Stock Issuance/Offering (2020): $93.8M backed by Undisclosed
Debt (2020): $52M with participation from CIBC
Key Investors in Vapotherm
QuestMark Partners
QuestMark Partners is an expansion-stage investment firm that focuses on partnering with exceptional management teams to build market-leading companies. Their investment strategy emphasizes long-term success and market leadership, particularly in sectors such as enterprise software, healthcare IT, and tech-enabled business services.
Kaiser Permanente Ventures
Kaiser Permanente Ventures is a national leader in strategic venture investing in healthcare, focusing on advancing healthcare innovation. The company partners with entrepreneurs to build promising healthcare solutions that provide clear value for patients, providers, and healthcare delivery systems.
Gilde Healthcare
Gilde Healthcare is a specialized healthcare investment firm managing over €1.4 billion across three fund strategies: Venture & Growth in Healthcare, Private Equity in Healthcare, and Private Equity in Climate Solutions. The firm focuses on investing in businesses that enable better care at lower costs.
What's next for Vapotherm?
With substantial enterprise-level backing and a recent strategic investment, Vapotherm is poised for accelerated growth. The company is likely to leverage this capital to expand its product development pipeline, enhance its manufacturing capabilities, and broaden its market reach, both domestically and internationally. Further investment in research and development will be crucial to maintaining its competitive edge in the rapidly evolving medical device landscape. Strategic partnerships and potential acquisitions could also be on the horizon as Vapotherm aims to solidify its leadership in respiratory therapy.
See full Vapotherm company page
